Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Bladder Cancer

  Free Subscription


1 Anticancer Agents Med Chem
4 Arch Esp Urol
1 Asian Pac J Cancer Prev
1 Biosci Rep
1 BMC Urol
1 Can Urol Assoc J
1 Clin Genitourin Cancer
1 Curr Opin Virol
3 Eur Urol
1 Front Oncol
1 Gene
1 Hereditas
1 Histopathology
1 Int Braz J Urol
1 Int J Biol Sci
1 Int J Clin Oncol
1 J Exp Clin Cancer Res
1 Medicine (Baltimore)
1 Pan Afr Med J
1 Pathol Oncol Res
1 Photobiomodul Photomed Laser Surg
1 Protein Cell
1 Urol Oncol
1 Urologe A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Anticancer Agents Med Chem

  1. PANDEY P, Siddiqui MH, Behari A, Kapoor VK, et al
    Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
    Anticancer Agents Med Chem. 2019 Jul 25. pii: ACAMC-EPUB-99966.
    PubMed     Text format     Abstract available

    Arch Esp Urol

  2. FARAJ KS, Abdul-Muhsin HM, Navaratnam AK, Rose KM, et al
    Intracorporeal orthotopic neobladder formation: Why not to do it?
    Arch Esp Urol. 2019;72:318-325.
    PubMed     Text format     Abstract available

  3. GASTON R, Ramirez P
    Intracorporeal neobladder.
    Arch Esp Urol. 2019;72:309-317.
    PubMed     Text format     Abstract available

  4. MEDINA LG, Baccaglini W, Hernandez A, Rajarubendra N, et al
    Robotic intracorporeal ileal conduit: Technical aspects.
    Arch Esp Urol. 2019;72:299-308.
    PubMed     Text format     Abstract available

  5. GAYA JM, Vila-Reyes H, Gavrilov P, Territo A, et al
    Robotic radical cystectomy.
    Arch Esp Urol. 2019;72:293-298.
    PubMed     Text format     Abstract available

    Asian Pac J Cancer Prev

  6. ELSHARKAWI F, Elsabah M, Shabayek M, Khaled H, et al
    Urine and Serum Exosomes as Novel Biomarkers in Detection of Bladder Cancer.
    Asian Pac J Cancer Prev. 2019;20:2219-2224.
    PubMed     Text format     Abstract available

    Biosci Rep

  7. TSAI TF, Lin JF, Lin YC, Chou KY, et al
    Cisplatin contributes to programmed death-ligand 1 (PD-L1) expression in bladder cancer through ERK1/2 - AP-1 signaling pathway.
    Biosci Rep. 2019 Jul 24. pii: BSR20190362. doi: 10.1042/BSR20190362.
    PubMed     Text format     Abstract available

    BMC Urol

  8. YANG Z, Fu B, Zhou L, Xu J, et al
    RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
    BMC Urol. 2019;19:69.
    PubMed     Text format     Abstract available

    Can Urol Assoc J

  9. TAN GH, Kuk C, Zlotta AR
    Are there differences among Bacillus Calmette-Guerin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle invasive bladder cancer? The jury is still out but the answer is likely no.
    Can Urol Assoc J. 2019 Jul 23. pii: cuaj.5923. doi: 10.5489/cuaj.5923.
    PubMed     Text format    

    Clin Genitourin Cancer

  10. HAQUE W, Verma V, Aghazadeh M, Darcourt J, et al
    Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Jul 2. pii: S1558-7673(19)30204.
    PubMed     Text format     Abstract available

    Curr Opin Virol

  11. STARRETT GJ, Buck CB
    BK polyomavirus is a cause of bladder cancer.
    Curr Opin Virol. 2019;39:8-15.
    PubMed     Text format     Abstract available

    Eur Urol

  12. COMPERAT E, Amin M, Reuter V
    Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of Wor
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30541.
    PubMed     Text format    

  13. RIJNDERS M, van der Veldt AAM, Zuiverloon TCM, Grunberg K, et al
    PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Eur Urol. 2019;75:538-540.
    PubMed     Text format    

  14. VAN DIJK N, Funt SA, Blank CU, Powles T, et al
    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    Eur Urol. 2019;75:435-444.
    PubMed     Text format     Abstract available

    Front Oncol

  15. PAN S, Zhan Y, Chen X, Wu B, et al
    Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices.
    Front Oncol. 2019;9:613.
    PubMed     Text format     Abstract available


  16. BOURAS E, Karakioulaki M, Bougioukas KI, Aivaliotis M, et al
    Gene promoter methylation and cancer: An umbrella review.
    Gene. 2019;710:333-340.
    PubMed     Text format     Abstract available


  17. CHEN Z, Liu G, Hossain A, Danilova IG, et al
    A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival.
    Hereditas. 2019;156:24.
    PubMed     Text format     Abstract available


  18. CHENG L, Berney DM
    Annual review issue: Urologic pathology: a remarkable journey of innovation.
    Histopathology. 2019;74:3.
    PubMed     Text format    

    Int Braz J Urol

  19. LUNNEY A, Haynes A, Sharma P
    Moderate or severe LUTS is associated with increased recurrence of non - muscle - invasive urothelial carcinoma of the bladder.
    Int Braz J Urol. 2019;45:306-314.
    PubMed     Text format     Abstract available

    Int J Biol Sci

  20. GAO Y, Liu S, Guo Q, Zhang S, et al
    Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Int J Biol Sci. 2019;15:1488-1499.
    PubMed     Text format     Abstract available

    Int J Clin Oncol

  21. DOTSON A, May A, Davaro F, Raza SJ, et al
    Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy.
    Int J Clin Oncol. 2019;24:706-711.
    PubMed     Text format     Abstract available

    J Exp Clin Cancer Res

  22. TONG Z, Sathe A, Ebner B, Qi P, et al
    Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer.
    J Exp Clin Cancer Res. 2019;38:322.
    PubMed     Text format     Abstract available

    Medicine (Baltimore)

  23. CHEN X
    MiR-101 acts as a novel bio-marker in the diagnosis of bladder carcinoma.
    Medicine (Baltimore). 2019;98:e16051.
    PubMed     Text format     Abstract available

    Pan Afr Med J

  24. SHAMALIRWA BB, Wembonyama O, Tidahy R, Mellas S, et al
    [Metastatic bladder metachrone to a kaposi sarcoma cancer at a therapeutic impasse: about a case].
    Pan Afr Med J. 2019;32:218.
    PubMed     Text format     Abstract available

    Pathol Oncol Res

  25. STEC R, Cierniak S, Lubas A, Brzoskowska U, et al
    Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer.
    Pathol Oncol Res. 2019 Jun 19. pii: 10.1007/s12253-019-00678.
    PubMed     Text format     Abstract available

    Photobiomodul Photomed Laser Surg

  26. KONECKI T, Kutwin P, Lowicki R, Juszczak AB, et al
    Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.
    Photobiomodul Photomed Laser Surg. 2019 Jul 24. doi: 10.1089/photob.2019.4634.
    PubMed     Text format     Abstract available

    Protein Cell

  27. JIANG S, Wang J, Yang C, Tan R, et al
    Continuous culture of urine-derived bladder cancer cells for precision medicine.
    Protein Cell. 2019 Jul 25. pii: 10.1007/s13238-019-0649.
    PubMed     Text format    


  28. CHEREMISIN D, Gavrilov P, Andropova P
    A case of renal tuberculosis following BCG therapy for bladder cancer.
    QJM. 2019 Jul 25. pii: 5538982. doi: 10.1093.
    PubMed     Text format     Abstract available

    Urol Oncol

  29. GUNLUSOY B, Bolat D, Degirmenci T
    Re: "Monopolar vs. bipolar transurethral resection for nonmuscle invasive bladder carcinoma: A post hoc analysis from a randomized controlled trial".
    Urol Oncol. 2019;37:177-178.
    PubMed     Text format    

    Urologe A

  30. VOM DORP F
    [Organ preservation in cancer of the upper urinary tract].
    Urologe A. 2019;58:22-24.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.